A flare of pre-existing erythema multiforme following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine

M J Lavery, S Nawimana, Nawimana S, Parslew R, R Parslew, L Stewart, Stewart L
Clinical and experimental dermatology · 2021 · vol. 46(7) , pp. 1325–1327 · doi:10.1111/ced.14714 · PMID:33914926 · PMC9213915
Case report OA: gold
📄 Open PDF View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-24 ⓘ

This report describes a case of erythema multiforme flare following the BNT162b2 COVID-19 vaccine, noting no direct relation to endometriosis or adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

MeSH descriptors

COVID-19 COVID-19 Vaccines Erythema Multiforme Administration, Topical BNT162 Vaccine Clobetasol Clobetasol Clobetasol COVID-19 COVID-19 COVID-19 COVID-19 COVID-19 Vaccines COVID-19 Vaccines COVID-19 Vaccines Erythema Multiforme Erythema Multiforme Erythema Multiforme Female Glucocorticoids

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-18T09:30:06.152893+00:00
pubmed
last seen: 2026-10-08T21:30:48.200749+00:00
unpaywall
last seen: 2026-10-19T06:34:38.229974+00:00